HAL shares in focus as India receives second GE-404 engine for LCA Mark 1A fighter jet programme
The Indian Air Force has already placed orders for 83 of these fighter jets. Additionally, a proposal to procure 97 more LCA Mark 1A aircraft is at an advanced stage following clearance from the Ministry of Defence.
Investors and analysts are closely tracking these developments for their potential impact on HAL's future order book and production cycle.
India on Monday received the second GE-404 engine from the US for the LCA Mark 1A fighter jet aircraft programme. Indian public sector firm Hindustan Aeronautics Limited (HAL) is expected to receive 12 GE-404 engines by the end of this financial year. The engines will be fitted… pic.twitter.com/RkZTUmKLqm
— ANI (@ANI) July 15, 2025
Hindustan Aeronautics Limited (HAL) shares traded in a narrow range today. The stock opened at ₹4,899 and touched a high of ₹4,932, while the day's low was ₹4,890.70. HAL is currently trading well below its 52-week high of ₹5,535 but remains far above its 52-week low of ₹3,046.05
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Dr Reddy's Laboratories Q1 Results: Revenue jumps 11.4% YoY to Rs 8,545 crore, net profit marginally up
Dr. Reddy's Laboratories kicked off the fiscal year on a solid note, posting its Q1 FY26 results with a healthy revenue increase but a slight dip in margins. The Hyderabad-based pharma giant reported a net profit of ₹1,417.8 crore, up 1.8% from ₹1,392 crore in the same quarter last year. Revenue for the quarter stood at ₹8,545 crore, marking a strong 11.4% year-on-year (YoY) growth compared to ₹7,672.7 crore in Q1 FY25. The company's operating performance also showed improvement, with EBITDA rising 5% YoY to ₹2,278 crore, up from ₹2,160 crore in the previous year. However, the EBITDA margin contracted to 26.7%, compared to 28.2% in Q1 FY25, indicating cost pressures or product mix changes impacting profitability. One key weak spot was in the North American market, where sales declined by 11% YoY to ₹3,410 crore, down from ₹3,846 crore. This drop may reflect pricing pressure and competitive dynamics in the generics space. In the meantime, Dr Reddy's Laboratories shares closed at ₹1,248.00 today, slightly higher than the opening price of ₹1,240.20. The stock touched an intraday high of ₹1,252.10 and a low of ₹1,231.00 during the session. Over the past year, the stock has seen a 52-week high of ₹1,421.49 and a low of ₹1,020.00. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
an hour ago
- Business Upturn
Natco Pharma offers to acquire 35.75% stake in South Africa's Adcock Ingram for Rs 2,000 crore
NATCO Pharma is making a bold move into the South African pharmaceutical market. The company's board has approved a major strategic investment to acquire a 35.75% stake in Adcock Ingram Holdings Limited, a leading pharmaceutical company based in South Africa. This includes NATCO's earlier holding of 0.80%. The acquisition, valued at around ₹2,000 crore (approximately ZAR 4 billion), involves buying over 5 crore shares from public shareholders and Adcock's treasury. NATCO has offered ZAR 75 (around USD 4.27) per share in an all-cash deal. If accepted, NATCO will join Bidvest, which holds the remaining 64.25%, as one of the two key stakeholders in Adcock Ingram. Adcock Ingram, founded back in 1890, operates across four main verticals—Prescription, OTC, Consumer, and Hospital products. In the financial year ending June 2024, it posted revenue of ZAR 9.6 billion (about USD 536 million), with a healthy EBITDA margin of 14.6% and net profit of ZAR 814 million (USD 45 million). This deal is part of NATCO's broader push to expand its global footprint. The company has also decided to set up a new wholly owned subsidiary in South Africa—NATCO Pharma South Africa Proprietary Limited—with an investment cap of ₹2,100 crore. The new entity will act as a holding and operational base to manage its local investments and business in the region. At the same time, NATCO plans to simplify its overseas structure by liquidating Time Cap Overseas Limited, a current wholly owned subsidiary. Post-liquidation, its Brazilian arm, NatcoFarma do Brasil Ltda., will come under direct ownership of NATCO Pharma. This acquisition is expected to unlock long-term value for both companies. For Adcock, it brings in NATCO's strength in R&D, dossier filing, IP access, and reach into regulated markets. NATCO, on the other hand, gets a foothold in a growing market and a chance to synergize operations with a respected local player. The transaction is likely to close by December 2025, subject to approvals from regulators in India and South Africa. If all goes as planned, Adcock Ingram may also be delisted from the Johannesburg Stock Exchange (JSE). Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
2 hours ago
- Business Upturn
Nifty top gainers today, July 23: Tata Motors, Bharti Airtel, Shriram Finance, Apollo Hospitals and more
By Aman Shukla Published on July 23, 2025, 15:38 IST Indian stock markets ended on a strong note on July 23, with benchmark indices rallying on the back of gains in heavyweight stocks. The Nifty 50 closed above the key 25,200 mark for the first time, settling at 25,219.90, up 0.63%. The Sensex also saw significant traction, rising by 539.83 points to close at 82,726.64. The market rally was driven by strong buying in frontline stocks, particularly from the auto, financial, and telecom sectors. Below is a detailed look at the top gainers of the Nifty 50 (as per Trendline) for the day. Nifty 50 Top Gainers on July 23 Tata Motors closed at ₹690.9, up 2.6% Bharti Airtel closed at ₹1,948.7, up 2.2% Shriram Finance closed at ₹654, up 2.2% Apollo Hospitals closed at ₹7,389, up 2.0% Bajaj Finance closed at ₹968, up 1.6% Jio Financial Services closed at ₹315, up 1.4% Bajaj Auto closed at ₹8,394, up 1.2% Maruti Suzuki closed at ₹12,638, up 1.2% Adani Enterprises closed at ₹2,615.5, up 1.1% Bajaj Finserv closed at ₹2,061, up 1.1% Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Apollo HospitalsBharti AirtelNiftyShriram FinanceTata Motors Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
